Format
Sort by
Items per page

Send to

Choose Destination

Best matches for metastatic melanoma to CNS:

Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. Papadatos-Pastos D et al. Expert Rev Anticancer Ther. (2013)

Metastatic melanoma to the brain: surgery and radiation is still the standard of care. Nicholas S et al. Curr Treat Options Oncol. (2013)

Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Dzienis MR et al. Melanoma Res. (2014)

Search results

Items: 1 to 20 of 261

1.

Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma.

Byun J, Park ES, Hong SH, Cho YH, Kim YH, Kim CJ, Kim JH, Lee S.

Clin Neurol Neurosurg. 2018 Jan;164:32-38. doi: 10.1016/j.clineuro.2017.11.012. Epub 2017 Nov 20.

PMID:
29156329
2.

Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies.

Arnett ALH, Reynolds MM, Pulido JS, Parney IF, Laack NN.

Stereotact Funct Neurosurg. 2017 Nov 4;95(6):363-368. doi: 10.1159/000478271. [Epub ahead of print]

PMID:
29131131
3.

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.

4.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES.

J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.

PMID:
28968165
5.

Demographics and Incidence of Histologically Confirmed Intracranial Tumors: A Five-year, Two-center Prospective Study.

Stoyanov GS, Dzhenkov DL, Kitanova M, Ghenev P, Tonchev AB.

Cureus. 2017 Jul 16;9(7):e1476. doi: 10.7759/cureus.1476.

6.

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Adler NR, Wolfe R, Kelly JW, Haydon A, McArthur GA, McLean CA, Mar VJ.

Br J Cancer. 2017 Sep 26;117(7):1026-1035. doi: 10.1038/bjc.2017.254. Epub 2017 Aug 8.

PMID:
28787433
7.

Primary Amelanotic CNS Melanoma: Case Report and Literature Review.

Mayer S, Mauer UM, Mathieu R, Hackenbroch C, Knupfer J, Schulz C.

J Neurol Surg A Cent Eur Neurosurg. 2018 Jan;79(1):96-100. doi: 10.1055/s-0037-1604326. Epub 2017 Jul 27.

PMID:
28750450
8.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA.

Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077.

PMID:
28444227
9.

Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, Weller M.

Neuro Oncol. 2017 Feb 1;19(2):162-174. doi: 10.1093/neuonc/now241.

10.

Targeted Therapies for Melanoma Brain Metastases.

Berghoff AS, Preusser M.

Curr Treat Options Neurol. 2017 Apr;19(4):13. doi: 10.1007/s11940-017-0449-2. Review.

11.

Nanotechnology for the treatment of melanoma skin cancer.

Naves LB, Dhand C, Venugopal JR, Rajamani L, Ramakrishna S, Almeida L.

Prog Biomater. 2017 May;6(1-2):13-26. doi: 10.1007/s40204-017-0064-z. Epub 2017 Mar 16. Review.

12.

Sequencing brain metastases and opportunities for targeted therapies.

Chukwueke UN, Brastianos PK.

Pharmacogenomics. 2017 Apr;18(6):585-594. doi: 10.2217/pgs-2016-0170. Epub 2017 Mar 14. Review.

PMID:
28290769
13.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

14.

Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.

Le Rhun E, Taillibert S, Chamberlain MC.

Cancer Control. 2017 Jan;24(1):22-32. Review.

PMID:
28178709
15.

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Glitza Oliva I, Tawbi H, Davies MA.

Cancer J. 2017 Jan/Feb;23(1):68-74. doi: 10.1097/PPO.0000000000000237. Review.

16.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K.

Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641.

PMID:
27993793
17.

Early Diagnosis of Brain Metastases Using a Biofluids-Metabolomics Approach in Mice.

Larkin JR, Dickens AM, Claridge TD, Bristow C, Andreou K, Anthony DC, Sibson NR.

Theranostics. 2016 Sep 12;6(12):2161-2169. eCollection 2016.

18.

Histopathologic diagnosis of brain metastases: current trends in management and future considerations.

Bekaert L, Emery E, Levallet G, Lechapt-Zalcman E.

Brain Tumor Pathol. 2017 Jan;34(1):8-19. doi: 10.1007/s10014-016-0275-3. Epub 2016 Nov 22. Review.

PMID:
27878432
19.

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA.

Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16.

PMID:
27864013
20.

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.

Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB.

Oncotarget. 2016 Dec 20;7(51):85430-85436. doi: 10.18632/oncotarget.13397.

Supplemental Content

Loading ...
Support Center